At a glance
- Originator Bayer Schering Pharma
- Class Antineoplastics
- Mechanism of Action Aromatase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Breast cancer
Most Recent Events
- 19 Jun 2001 Discontinued-Preclinical for Breast cancer in Germany (Unknown route)
- 17 Apr 1997 Preclinical development for Breast cancer in Germany (Unknown route)